Researchers at Houston Methodist Research Institute were awarded a nearly $4 million grant from the National Institute of Allergy and Infectious Diseases to study a transcutaneously refillable implant that delivers pre-exposure prophylaxis drugs to people who are at risk of being exposed to HIV.
Woburn, MA-based Aphios said it landed a subcontract for the nanoformulation of a new superhydrophobic anticancer drug called Brefeldin A.
The New Jersey Institute of Technology received a $1 million grant from the W. M. Keck Foundation it will use to study new materials for nanotechnology.
Researchers at Memorial Sloan Kettering have uncovered a new way to target drugs specifically to cancer sites in the body, including metastatic tumors.
Researchers at Canada’s University of Waterloo and Harvard Medical School have developed a mathematical model that can shrink tumors and prevents resistance in aggressive cancers by activating two drugs within the same cell at the same time.
Researchers have presented new information on a novel variant of what is known as DNA origami that could lead to developments in biomolecular science and nanotechnology.
Carnegie Mellon scientists are making use of carbon nanotubes for drug delivery. The tubes are made of very simple components so that they are more readily taken up by cells.
Researchers from Cornell University have developed a combination therapy to treat cancers such as prostate and colon.
Russian scientists at the Lomonosov Moscow State University, using computer models, report that it should be possible in the coming years to create double-shelled nano-capsules that could be used for targeted drug delivery. And they could be relatively inexpensive to produce, too.